Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (250)	11/9/2001 2:30:48 PM
From: nigel bates	Read Replies (1) \| Respond to of 1022

Xoma..CEO says it is talking to 14 companies that will need to license its cell expression technology... George, it might be worth an effort to put this in context. Dyax also holds IP which is 'fundamental' to the practice of phage display. It has fifty or so licensees. Even assuming Xoma's IP is as fundamental as it claims - & there clearly had been less of a rush to sign up than DYAX has experienced - if they get too greedy, there could always be the possibility (as I understand it, & FWIW...) of running with Crucell's PER.C6(TM) cell line. Bottom line, I'm not going to get over excited. nig